Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Legal Names
Legal name
Similar Companies1000
VBL THERAPEUTICS
VBL Therapeutics is a clinical stage biotech company that develops innovative treatments for cancer and immune-inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Sagimet Biosciences
Sagimet Biosciences develops novel therapeutics to treat metabolic diseases and specific cancers.
Sector
Subsector
Keywords
Location
total rounds
total raised
Vaccinex
Vaccinex develops targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Quintessence Biosciences
Quintessence Biosciences is a biopharmaceutical company developing protein-based therapeutics to fight cancer.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 05.08.2024. Their latest investor Norwest Venture Partners. Their latest round Series C
Deep Track Capital
Deep Track Capital is a Greenwich-based investment firm focused on life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Wellington Management
Wellington Management manages over $1 trillion for clients in 60 countries.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Frazier Healthcare Partners
Frazier Healthcare Partners is a private equity firm that provides growth and venture capital to healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors17
Number of lead investors
Number of investors
Norwest Venture Partners
Norwest is a global venture capital and growth equity investment firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Deep Track Capital
Deep Track Capital is a Greenwich-based investment firm focused on life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Driehaus Capital Management
Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders3
P. Kent Hawryluk
Kent Hawryluk is a President & CEO at MBX Biosciences, Inc. He attended Princeton University.
current job
P. Kent Hawryluk
Tim Knickerbocker
Timothy Knickerbocker is an Indiana native and Purdue University alumnus, seasoned by professional employment in the Midwest and California. He has served in leadership roles in project management and operations pertaining to the life sciences. Mr. Knickerbocker is COO and one of our co-founders. Prior to his time at MBX, Mr. Knickerbocker successfully led teams in the building of some of the most technically advanced healthcare facilities in the country. He is currently complementing his operational duties at MBX with an Executive MBA education from the Anderson School of Management at UCLA.
current job
organization founded
Tim Knickerbocker
Kent Hawryluk
Kent Hawryluk has nearly 20 years’ experience as a life sciences entrepreneur, leader and investor. Mr. Hawryluk is President & CEO and one of our co-founders. Mr. Hawryluk was a Co-founder and Chief Business Officer of Avidity Biosciences, a genetic medicines company, from January 2013 to December 2019. Under his leadership, Avidity raised $130 million in equity financings and initiated a significant strategic partnership with Eli Lilly. Previously, he served as Co-founder and CEO of MB2, a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Prior to MB2 and Avidity, Mr. Hawryluk co-founded Marcadia Biotech and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia, a pioneer in peptide multi-agonists of incretin receptors, was acquired by Roche in December 2010. Mr. Hawryluk served as a director of Gemphire Therapeutics, a public clinical-stage cardiovascular drug company, from February 2015 to February 2019. He has served as partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund, since January 2003. Mr. Hawryluk holds a BA from Princeton University, an MBA from Kellogg School of Management at Northwestern University, and an MS, Biology from Purdue University.
current job
organization founded
Kent Hawryluk
Employee Profiles6
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range